Novel 5'-deoxythreosyl purine phosphonic acid analogues containing a 2'-electropositive moiety such as fluorine atom, were designed and synthesized from commercially available 1,3-dihydroxy acetone. Condensation successfully proceeded from a glycosyl donor 6 under Vorbrüggen conditions and cross-metathesis gave the desired phosphonate analogues 7a, 7b, 17a and 17b. The synthesized nucleoside phosphonic acid analogues 13, 16, 23, 26, 28 were subjected to antiviral screening against HIV-1. The bis(SATE) adenine analogue 28 exhibited significant in vitro activities against HIV-1.
Introduction
As mimics of nucleoside monophosphates, phosphonate analogues exert their antiviral effect following sequential activation by cellular kinases to their diphosphate derivatives (nucleoside triphosphate analogues) which act as potent inhibitors of viral polymerases.
1 The selective inhibition of viral polymerases, as opposed to host cell DNA polymerases, is critical for the therapeutic use of such compounds. Various attempts to improve selectivity indices have led to nucleoside analogues with a modified furanose ring system due to the introduction of an electropositive moiety at the 2'-position of the furanose ring, 2 and recently, a nucleoside analogue with a fluorine atom at this position, GS-9148 (1), was reported to show excellent anti-HIV activity (Figure 1 ).
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Threose phosphonate nucleosides, 4 such as, PMDTA (2) and PMDTT (3), have been assembled from natural precursor molecules. Furthermore, it has been demonstrated threose nucleic acids (TNA) form thermal stable duplexes with DNA and RNA that are reminiscent of the natural associations of nucleic acids. 5 Moreover, diphosphates of threose nucleosides are accepted as substrates by several polymerases, and can be enzymatically incorporated into DNA. 6 In addition, these nucleosides are also accepted as substitutes for ribonucleosides at the catalytic site of hammerhead ribozyme, although the catalytic efficiency of ribozyme is then significantly reduced. 7 PMDTA has a phosphonomethoxy group at the 3'-position of its furanose ring and no substituent at the 4'-position. 8 This absence of a 4'-hydroxymethyl group avoids problems of steric hindrance during phosphorylation reactions with kinases. To study the influences of different substituents on anti-HIV activity further, we undertook to synthesize 2'-fluorinated analogues of PMDTA.
Several 5'-phosphate isosteres have been used to prepare nucleoside phosphonates. As shown in Figure 1 , compound 4 9 is a simple 5'-deoxynucleoside phosphonate, in which the 5'-oxygen of a nucleoside phosphate is replaced by methylene group. Importantly, all resultant phosphonates mimic the overall shape and geometry of nucleoside monophosphates.
Stimulated by the findings that 2'-electropositive nucleoside analogues and 5'-deoxyphosphonic acid nucleosides have excellent antiviral activities, we sought to synthesize a novel class of nucleosides consisting of 2'-fluorinated-5'-deoxythreosylphosphonic acid analogues in order to find therapeutics that are more effective against HIV.
Results and Discussion
As depicted in Scheme 1, target compounds were prepared from the fluorinated glycosyl donor 6, which was readily prepared from 1,3-dihydroxyacetone 5, as previously described. 10 The synthesis of adenine nucleoside was carried out by Vorbrüggen condensation 11 of compound 6 with silylated 6-chloropurine using TMSOTf as a catalyst in DCE to give the protected 6-chloropurine derivatives 7a and 7b, respectively. Strong NOE (0.8%) of H-1' ↔ CH-3', which showed a 1',3'-cis relationship, was observed. According to this result, the 3'-hydroxymethyl group and the 1'-purine base of 7b were located on the β face. On the other hand, for 7a compound, weak NOE (0.4%) of H-1' ↔ CH-3', demonstrated a 1',3'-trans relationship (Figure 2) .
For the homologation, removal of the silyl protecting group of 7b using tetra n-butylammonium fluoride (TBAF) gave the primary alcohol 8. Dess-Martin oxidation 12 of the alcohol of 8 gave the aldehyde 9, which was subjected to Wittig olefination 13 to give compound 10 without loss of the 3'-stereochemistry. Cross-metathesis 14 of 10 with vinyl diethylphosphonate using a 2 nd generation Grubbs catalyst 15 gave the vinylidene phosphonate nucleoside analogue 11 in 57% yield. The chlorine group of the purine analogue 11 was then converted to amine with methanolic ammonia at 62 o C to give the corresponding adenosine phosphonate derivative 12 at in 63% yield. Hydrolysis of the diethyl phosphonate functional groups of 12 by treatment with bromotrimethylsilane in CH 3 CN in the presence of 2,6-lutidine then gave the adenosine phosphonic acid derivative 13.
16 When the vinylidene phosphonate was saturated under transfer catalytic hydrogenation conditions 17 it produced the ethyl phosphonate nucleoside analogue 14 in 74% yield. The adenine phosphonic acid analogue 16 was prepared using conditions similar to the ammonolysis and hydrolysis described to produce 13 (Scheme 2). The guanine analogues, 2-fluoro-6-chloropurine 18 was condensed with the glycosyl donor 6 using conditions similar to those used for the preparation of 7a and 7b to give the analogues 17a (31%) and 17b (32%) from 6-chloropurine (Scheme 3). A complete NOE study allowed the unambiguous determination of the relative stereochemistries of purine analogues as described for 7a and 7b. Homologation was performed using reactions similar to those used to produce 10, such as desilylation, Dess-Martin oxidation and Wittig olefination. Cross-metathesis of 20 with diethylvinylphosScheme 1. Synthesis of threosyl-2'-fluoro-3'-vinylidene 6-chloropurine analogue. Bubbling ammonia into the compound 21 gave separable 2-fluoro-6-aminopurine 19 22a (14%) and 2-amino-6-chloropurine 22b (45%) analogues, respectively. The 2-amino-6-chloropurine derivative 22b was treated with TMSBr to provide phosphonic acid and sequentially treated with sodium methoxide and 2-mercaptoethanol in methanol to give the desired guanine phosphonic acid 23 (Scheme 4). 20 Furthermore, the guanine phosphonic acid analogue 26 was synthesized from 21 via transfer catalytic hydrogenation, ammonolysis, and hydrolysis using conditions similar to those described for the synthesis of the adenine 6, line derivative 16. To synthesize the thioester-protected analogue, compound 16 was reacted with thioester 27 21 in the presence of 1-(2-mesitylenesulfonyl)-3-nitro-1H-1,2,4-triazole (MSNT) 22 to provide the bis(SATE) derivative as a target compound 28 (Scheme 5).
Antiviral Activity. The antiviral activities of phosphonate nucleosides are explained by their intracellular metabolism to diphosphates, subsequent incorporation into the viral genome, and chain termination. 23 MT-4 cells (1 × 10 5 cell/ mL) were infected with HIV-1 (HTLV-III B strain) at a multiplicity of infection (MOI) of 0.02, and then cultured in the presence of various concentrations of the test compounds. After a 4-day incubation at 37 o C, numbers of viable cells were determined using the 3-(4,5-di-methylthiazole-2-yl)-2,5-diphenyltetrazolium bromide method. The cytotoxicities of the compounds were evaluated in parallel with their antiviral activities, by determining the viabilities of mockinfected cells.
24 Compounds 13, 16, 23 , 26 and 28 were tested against HIV-1, and the adenine analogue 16 showed moderate antiviral activity (Table 1) . However, other three 5'-deoxyphosphonic acid nucleoside analogues showed weak or no anti-HIV activity at concentrations up to 100 μM.
In summary, based on the potent anti-HIV activities of 2'-electropositive nucleosides and 5'-deoxyphosphonic acid nucleoside analogues, we designed and successfully synthesized novel 2'-fluoro-5'-deoxyphosphonic acid nucleoside analogues starting from 1,3-dihydroxy acetone. The synthesized bis(SATE) adenine analogue 28 showed significant activity in a cell-based assay than the 2'-modified guanine phosphonic acid analogues 13, 23 and 26. Since 2'-fluorinated guanine nucleoside derivatives are not perfect mimics of the ribofuranose moiety, mechanisms of virus inhibition, that is, phosphorylation or the inhibition of RNA synthesis, might be impaired for these compounds. For the discovery of improved antiviral nucleoside derivatives, bis(SATE) analogue 28 was synthesized and assayed for anti-HIV activity using an in vitro assay system, It showed much improved anti-HIV activity than adenine nucleoside phosphonic acid 16 ( Table 1) . As shown in the superimposition model of PMDTA (2) and the corresponding analogue 16 (Figure 3 ), discrepancies of phosphonic acid regions are more pronounced than those of the base moiety. Note the furanose puckering of PMDTA (2) is closer to that of the adenine analogue 16.
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Experimental Section
Uncorrected melting points were determined on a Meltemp II laboratory device. NMR spectra were recorded on a JEOL 300 Fourier transform spectrometer (JEOL, Tokyo, Japan); chemical shifts are reported in parts per million (δ) and signals are reported as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), or dd (doublet of doublets). UV spectra were obtained on a Beckman DU-7 spectrophotometer (Beckman, South Pasadena, CA, USA). MS spectra were collected in electrospray ionization (ESI) mode. Elemental analyses were performed using a Perkin-Elmer 2400 analyzer (Perkin-Elmer, Norwalk, CT, USA). TLC was performed on Uniplates (silica gel) purchased from Analtech Co. (7558, Newark, DE, USA). All reactions were carried out in a nitrogen atmosphere unless otherwise specified. Dry dichloromethane, benzene, and pyridine were obtained by distillation from CaH 2 . Dry THF was obtained by distillation from Na and benzophenone immediately prior to use.
(rel)-(1'S,2'R,3'S)-9-(3'-t-Butyldimethylsilanyloxymethyl-2'-fluoro-tetrahydrofuran-1'-yl) 6-chloropurine (7a) and (rel)-(1'R,2'R,3'S)-9-(3'-t-butyldimethylsilanyloxymethyl-2'-fluoro-tetrahydrofuran-1'-yl) 6-chloropurine (7b): 6-Chloropurine (216 mg, 1.4 mmol), anhydrous HMDS (10 mL), and a catalytic amount of ammonium sulfate (14 mg) were refluxed to a clear solution, and the solvent was then distilled off under anhydrous conditions. The residue obtained was dissolved in anhydrous 1,2-dichloroethane (8 mL), and to this mixture, a solution of 6 (175 mg, 0.6 mmol) in dry DCE (10 mL) and TMSOTf (311 mg, 1.4 mmol) was added, and stirred for 8 h at rt. The reaction mixture was quenched with 5.0 mL of saturated NaHCO 3 , stirred for 1 h, filtered through a Celite pad, and the filtrate obtained was then extracted twice with CH 2 Cl 2 (80 mL). Combined organic layers were dried over anhydrous MgSO 4 , filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (EtOAc/hexane/MeOH, 4:1:0.01) to give compounds 7a (74 mg, 32%) and 7b (79 mg, 34% + . (rel)-(1'R,2'R,3'S)-9-(3'-Hydroxymethyl-2'-fluoro-tetrahydrofuran-1'-yl) 6-chloropurine (8) . To a solution of 7b (2.54 g, 6.56 mmol) in THF (12 mL), TBAF (7.7 mL, 1.0 M solution in THF) was added at 0 o C. The mixture was stirred overnight at rt and concentrated in vacuo. The residue was purified by silica gel column chromatography (Hexane/ EtOAc/MeOH, 2:1:0.05) to give 8 (1.59 g, 89%): + . (rel)-(1'R,2'R,3'R)-9-(3'-Carbaldehyde-2'-fluoro-tetrahydrofuran-1'-yl) 6-chloropurine (9). Compound 8 (290 mg, 1.066 mmol) was dissolved in anhydrous CH 2 Cl 2 (8 mL), and to this solution was added Dess-Martin reagent (588 mg, 1.38 mmol). The mixture was stirred for 3 h at ambient temperature, concentrated and the residue was purified by silica gel column chromatography using Hexane/ EtOAc (1:4) as eluent. A second column, which was also eluted with EtOAc, was necessary to remove traces of DessMartin reagent-related impurities to give 9 (253 mg, 88%): quenched with saturated sodium bicarbonate solution, and then partitioned between saturated sodium bicarbonate solution and ethyl acetate. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. Combined extracts were dried over anhydrous sodium sulfate, filtered, concentrated in vacuo, and chromatographed (HexaneEtOAc, 1:2) to afford 10 (76 mg, 61%) as a colorless oil. (rel)-(1'R,2'R,3'S)-Diethyl {9-(3'-vinyl-2'-fluoro-tetrahydrofuran-1'-yl) adenine} phosphonate (12). A solution of 11 (188 mg, 0.464 mmol) in saturated methanolic ammonia (7 mL) was stirred overnight at 66 ºC in a steel bomb, and volatiles were evaporated. The residue was purified by silica gel column chromatography (MeOH/CH 2 Cl 2 , 1:10) to give 12 (112 mg, 63%) as a white solid: UV (MeOH) λ max 261. (rel)-(1'R,2'R,3'S)-Diethyl {9-(3'-ethyl-2'-fluoro-tetrahydrofuran-1'-yl) 6-chloropurine} phosphonate (14). A solution of vinyl phosphonate nucleoside analogue 13 (265 mg, 0.655 mmol) in methanol (8 mL) was added 10% Pd/C (10 mg) and cyclohexene (4 mL) under Ar. The reaction mixture was refluxed for 24 h. The reaction mixture was filtered through a pad of Celite, evaporated, and purified by silica gel column chromatography using methanol and methylene chloride (10:1) to give ethyl phosphonate analogue 14 (197 mg, 74%) as a white solid: (rel)-(1'R,2'R,3'S)-Diethyl {9-(3'-ethyl-2'-fluoro-tetrahydrofuran-1'-yl) adenine} phosphonate (15) . The adenine derivative 15 was prepared from the 6-chloropurine analogue 14 using an ammonolysis procedure similar to that described for 12: yield 60%; mp 172-174 ºC; UV (MeOH) λ max 260.5 nm; (rel)-(1'S,2'R,3'S)-9-(3'-t-Butyldimethylsilanyloxymethyl-2'-fluoro-tetrahydrofuran-1'-yl) 6-chloropurine (17a) and (rel)-(1'R,2'R,3'S)-9-(3'-t-Butyldimethylsilanyloxymethyl-2'-fluoro-tetrahydrofuran-1'-yl) 2-fluoro-6-chloropurine (17b). Condensation of 6 with 2-fluoro-6-chloropurine under Vorbruggen condensation conditions similar to those described for 7a and 7b gave 17a and 17b, respectively. Data for 17a: yield 31%; UV (MeOH) λ max 267.5 nm; + . (rel)-(1'R,2'R,3'S)-9-(3'-Hydroxymethyl-2'-fluoro-tetrahydrofuran-1'-yl) 2-fluoro-6-chloropurine (18) . Desilylation of 17b was performed using a procedure similar to that described for 8: yield 78%; UV (MeOH) λ max 269.5 nm; (rel)-(1'R,2'R,3'S)-9-(3'-Carbaldehyde-2'-fluoro-tetrahydrofuran-1'-yl) 2-fluoro-6-chloropurine (19) . Oxidation of 18 was performed using the Dess-Martin reaction conditions described for 9: yield 66%; (rel)-(1'R,2'R,3'S)-9-(3'-Vinyl-2'-fluoro-tetrahydrofuran-1'-yl) 2-fluoro-6-chloropurine} phosphonate (20) . Wittig olefination of the aldehyde 10 was performed using a procedure similar to that described for 10: yield 59%; (rel)-(1'R,2'R,3'S)-Diethyl {9-(3'-vinyl-2'-fluoro-tetrahydrofuran-1'-yl) 2-fluoro-6-chloropurine} phosphonate (21) . Phosphonate nucleoside analogue 21 was prepared from 20 using a cross metathesis procedure similar to that described for 11: yield 60%; (rel)-(1'R,2'R,3'S)-9-{(3'-Vinyl-2'-fluoro-tetrahydrofuran-1'-yl) guanine} phosphonic acid (23) . To a solution of 22b (159 mg, 0.379 mmol) in dry CH 3 CN (15 mL) was added trimethylsilyl bromide (0.0873 mL, 6.62 mmol) at room temperature. The mixture was stirred for 24 h, and solvent was removed by co-evaporation with methanol three times. The residue was dissolved in MeOH (15.0 mL) and 2-mercaptoethanol (105.5 mL, 1.52 mmol), and then NaOMe (80.6 mg, 1.52 mmol) was added. The mixture was refluxed for 18 h under N 2 , cooled, neutralized with glacial AcOH, and evaporated to dryness in vacuo. The residue obtained was co-evaporated from conc NH 4 OH (2 × 25 mL) and the resultant solid was triturated with acetone (2 × 10 mL). After evaporating the acetone, the residue was purified by preparative column chromatography using reverse-phase C18 silica gel and elution with water. Lyophilization of the appropriate fraction provided 23 (53.52 mg, 39%) as a yellowish salt (ammonium salt + . (rel)-(1'R,2'R,3'S)-Diethyl {9-(3'-ethyl-2'-fluoro-tetrahydrofuran-1-yl) 2-fluoro-6-aminopurine} phosphonate (25a) and (rel)-(1'R,2'R,3'S)-diethyl {9-(3'-ethyl-2'-fluorotetrahydrofuran-1-yl) 2-amino-6-chloropurine} phosphonate (25b). Ammonolysis of 24 using the same procedure described for 14 gave 25a and 25b. Data for 25a; yield 13%; UV (MeOH) λ max 261.5 nm; 
